Exact Sciences (EXAS) Return on Equity ROE from the fourth quarter 2025 to fourth quarter 2024 and annually, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Exact Sciences Corporation  (NASDAQ: EXAS)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare

Exact Sciences's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Exact Sciences in the fourth quarter 2025?
Exact Sciences Corporation recorded a cumulative net loss of $-208 million during 12 months ending in the fourth quarter 2025, resulting in a negative return on equity (ROE) of -8.51%.

Within the Medical Laboratories industry 18 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2025 from 1338 to 2769.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Equity Change -0.05 % -22.09 % -22.65 % -23.49 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -208 -987 -1,005 -1,020 -1,029
Return On Equity (TTM) -8.51 % -40.39 % -38.37 % -36.42 % -34.47 %
EXAS's Total Ranking # 2769 # 1338 # 2696 # 2321 # 1158
Equity (TTM) in Millions 2,401 2,501 2,469 2,397 2,402
Seq. Equity Change -4.01 % 1.3 % 3.03 % -0.22 % -25.18 %
Seq. Net Income Change - - - - -

Back to EXAS Management Effectiveness >> EXAS's 5 Years Annual ROE >> Compare EXAS ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 19
Sector # 241
Overall # 2769

Return On Equity Statistics
High Average Low
-5.56 %
-29.03 %
-57.16 %
(Jun 30 2024)   (Jun 30 2016)





EXAS Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2021		 (Dec 31 2020)
2020
Total Equity in Millions 2,401 2,402 3,145 3,043 2,823
Y / Y Equity Change -0.05 % -23.62 % 3.36 % 7.78 % 23.4 %
Net Income in Millions -208 -1,029 -204 -624 -849
Y / Y Net Income Change - - - - -
Return On Equity -8.66 % -42.83 % -6.49 % -20.49 % -30.05 %

Back to EXAS Management Effectiveness >> EXAS's 5 Years Annual ROE >> Compare EXAS ROE to its Competitors




More Return On Equity Ratios
Medical Laboratories Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
EXAS's' Return on Equity at Yahoo Finance
EXAS's Roe Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for EXAS's Competitors
Subscribers only: Roe for Exact Sciences's Suppliers
Subscribers only: Return On Equity for EXAS's Customers




Companies with similar Return On Equity at Dec 31 2025, within Healthcare Sector ROE

Date modified: 2026-06-22T16:30:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.